21 reports

Competitive Landscape ##. ## Abbvie ##. ## Biogen Idec ##. ## Bristol-Myers Squibb ##. ## Celgene ##. ## Celltrion ##. ## J& J ##. ## MedImmune ##. ## Merck ##. ## Novartis ##. ## Takeda List of Figures Figure ##-##: Representation of the Disease Progression in Rheumatoid Arthritis Figure ##-

  • Anti Rheumatic
  • Arthritis
  • Therapy
  • World

In more severe cases disease modifying anti-rheumatic drugs (DMARDs) may be prescribed.

  • Anti Rheumatic
  • Autoimmune Disease
  • Therapy
  • United States
  • World

In moderate to severe cases the treatment involves disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (Rheumatrex®).

  • Anti Rheumatic
  • Monoclonal Antibody
  • Therapy
  • United States
  • World

Some of these biologics are approved and used in more than one conditions.

  • Anti Rheumatic
  • Autoimmune Disease
  • Therapy
  • United States
  • World

Retail Pharmacies ## Figure ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. (## of ##) ## Figure ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. (## of ##) ## Chart ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. ## Figure ## ##: Ulcerative Colitis Market by Segment, U. S., 2014 –

  • Anti Rheumatic
  • Monoclonal Antibody
  • Therapy
  • United States
  • World
  • COMPANION DIAGNOSTIC ASSAY - COXIBS AND NSAIDS
  • COMPANION DIAGNOSTIC ASSAY - COXIBS AND NSAIDS PRODUCT OVERVIEW

Summary Firalis SAS (Firalis) is a biotechnology company that develops biomarkers and biomarker-based diagnostic kits.The company’s biomarker products comprise recombinant proteins and calibrants, Elisa kits, and monoclonal antibodies, among others. It offers biomarker services such as flow cytometry, metabolomics...

  • Anti Rheumatic
  • Biomarker
  • Chronic Disease
  • Immunochemistry Test
  • Firalis SAS

The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.

  • Anti Rheumatic
  • Arthritis
  • Monoclonal Antibody
  • Therapy
  • United States

Some of these biologics are approved and used in more than one conditions.

  • Anti Rheumatic
  • Autoimmune Disease
  • Therapy
  • United States
  • Market Size

Retail Pharmacies ## Figure ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. (## of ##) ## Figure ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. (## of ##) ## Chart ## ##: Drug Prices - Retail Vs Veteran, 2017, U. S. ## Figure ## ##: Crohn’s Disease Market by Segment, U. S., 2014 – ##

  • Anti Rheumatic
  • Monoclonal Antibody
  • Pathology
  • Therapy
  • United States

INTRODUCTION.............. ## ##.

  • Anti Rheumatic
  • United States
  • World
  • Demand
  • Market Shares
  • 4.1 Changes to Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs, 2015-2022
  • 5.1 Abbreviations

Rheumatoid Arthritis - Heat Map and Analysis Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders the mobility of the patient and can have...

  • Anti Rheumatic
  • Therapy
  • Japan
  • LATEST CLINICAL TRIALS NEWS ON JUVENILE RHEUMATOID ARTHRITIS
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Orencia may be used as monotherapy or concomitantly with diseasemodifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

  • Anti Rheumatic
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Pfizer Inc.
  • JAN 17, 2017: OXFORD PHARMASCIENCE GROUP: TECHNICAL, CLINICAL AND REGULATORY UPDATE

Ketorolac is an NSAID in the family of heterocyclic acetic acid derivatives which is used for moderate-to-severe pain, often prescribed in place of opioids.

  • Anti Rheumatic
  • Healthcare
  • Pharmaceutical
  • United Kingdom
  • Company

##: Total axial spondyloarthritis sales across the US, Japan, and five major EU markets, by country, 2016–## ## Figure ##: Total axial spondyloarthritis sales in the US, 2016–## ## Figure ##: Total axial spondyloarthritis sales across the five major EU markets, 2016–## ## Figure ##: Total axial

  • Anti Rheumatic
  • Therapy
  • European Union
  • Japan
  • United States

(Australia) ##.

  • Anti Rheumatic
  • Pharmaceutical
  • Therapy
  • World
  • Market Shares
  • sarilumab - Drug Profile
  • golimumab - Drug Profile

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Anti Rheumatic
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Anti Rheumatic
  • Arthritis
  • Clinical Trial
  • World
  • Pfizer Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Analgesic
  • Anti Rheumatic
  • Clinical Trial
  • World
  • Pain Therapeutics

The prominent features of this report are - ##.

  • Anti Rheumatic
  • Arthritis
  • Clinical Trial
  • Pharmaceutical
  • World
  • Clinical Trial Profile Snapshots

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Anti Rheumatic
  • Musculoskeletal Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • IBUPROFEN - DRUG PROFILE
  • ECP-1014 - DRUG PROFILE

Meloxicam is an oxicam derivative.

  • Anti Rheumatic
  • Chronic Disease
  • United States
  • Company
  • Product Initiative